Fibrotic encapsulation around medical implants affects millions of patients annually. Current approaches targeting inflammation or implant material properties have failed clinically, but the mechanical origins of implant-induced fibrosis remain unexplored. Here, we demonstrate that directional imbalance of mechanical forces (tension anisotropy) is the primary driver of fibroblast activation at implant-tissue interfaces, and that it can be eliminated through adhesive bonding strategies. Computational modeling reveals a mechanistic basis for successful adhesive anti-fibrotic interfaces: conventional sutured implants generate highly anisotropic stress fields between discrete suture anchor points that activate fibroblasts, while adhesive interfaces distribute forces isotropically, maintaining a mechanical environment that does not activate fibroblasts. In vivo experiments from the literature across multiple animal models confirm these predictions: as predicted, adhesive interfaces completely prevent fibrotic capsule formation for up to 12 weeks across diverse organs, while maintaining identical implant composition and geometry compared to sutured controls. Results establish tension anisotropy as a mechanical regulator of implant fibrosis and provide a mechanistic foundation explaining why adhesive interfaces succeed where all previous anti-fibrotic strategies have failed. By addressing the root mechanical cause of fibrosis, this mechanobiology-driven approach may enable a universal approach for preventing fibrosis across all categories of implantable medical devices.